Connor, Clark & Lunn Investment Management (CC&L)’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-38	Closed	-$26K	–	983
2017 Q1	$26K	Hold	38	–	–	﹤0.01%	883
2016 Q4	$27K	Hold	38	–	–	﹤0.01%	867
2016 Q3	$36K	Hold	38	–	–	﹤0.01%	812
2016 Q2	$54K	Hold	38	–	–	﹤0.01%	831
2016 Q1	$46K	Hold	38	–	–	﹤0.01%	800
2015 Q4	$48K	Buy	38 +3	+9%	+$3.91K	﹤0.01%	788
2015 Q3	$50K	Buy	35 +6	+21%	+$11.6K	﹤0.01%	692
2015 Q2	$63K	Hold	29	–	–	﹤0.01%	605
2015 Q1	$85K	Hold	29	–	–	﹤0.01%	541
2014 Q4	$95K	Buy	29 +1	+4%	+$3.54K	﹤0.01%	552
2014 Q3	$100K	Hold	28	–	–	﹤0.01%	523
2014 Q2	$116K	Hold	28	–	–	﹤0.01%	505
2014 Q1	$127K	Buy	+28	New	+$125K	﹤0.01%	648
2013 Q4	–	Sell	-7	Closed	-$29K	–	769
2013 Q3	$29K	Hold	7	–	–	﹤0.01%	513
2013 Q2	$74K	Buy	+7	New	+$77.5K	﹤0.01%	511

Other funds holding FRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s FRTX Position: Q2 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2017, closing a stake of 38 shares — an estimated $26K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in FRTX in Q2 2013 and held it in 15 quarters. The position peaked at $127K in Q1 2014. 28 funds tracked by Wall St. Rank hold FRTX as of Q2 2017.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 38 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $26K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 15 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $127K in Q1 2014.
28 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2017, filed 14 Aug 2017.